Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in alzheimer's disease and dementia with lewy Bodies

American Journal of Geriatric Psychiatry

Volumn 18, Issue 1, 2010, Pages 86-90

  Colloby, Sean J ^a   Perry, Elaine K ^a   Pakrasi, Sanjeet ^a   Pimlott, Sally L ^b   Wyper, David J ^c   McKeith, Ian G ^c   Williams, E David ^d   O'Brien, John T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

AD; DLB; SPM

Indexed keywords

5 IODO 3 (2 2 AZETIDINYLMETHOXY)PYRIDINE I 123; DONEPEZIL; GALANTAMINE; TRACER; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN MAPPING; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MALE; MENTAL DETERIORATION; NERVE DEGENERATION; PROGNOSIS; REGRESSION ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL PARAMETERS;

EID: 74349108977     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181b972aa     Document Type: Article

References (13)

1. Jones S, Sudweeks S, Yakel JL: Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999; 22:555-561
2. Gotti C, Moretti M, Bohr I, et al: Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies by immunopre-cipitation. Neurobiol Dis 2006; 23:481-489
3. Samuel W, Alford M, Hofstetter CR, et al: Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997; 56:499-508
4. Shinotoh H, Namba H, Fukushi K, et al: Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000; 48:194-200
5. Bohnen NI, Kaufer DI, Hendrickson R, et al: Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neu-rosci Lett 2005; 380:127-132
6. Kadir A, Almkvist O, Wall A, et al: PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 2006; 188:509-520
7. Sabri O, Kendziorra K, Wolf H, et al: Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 2008; 35(suppl 1):S30-S45
8. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944
9. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113-1124
10. O'Brien JT, Colloby SJ, Pakrasi S, et al: Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 2007; 78:356-362
11. Field AP: Discovering Statistics Using SPSS for Windows. London, SAGE Publications, 2000
12. Sabbagh MN, Reid RT, Hansen LA, et al: Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. J Neural Transm 2001; 108:1149-1157
13. Bullock R, Lane R: Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholines-terase. Curr Alzheimer Res 2007; 4:277-293